Our studies unexpectedly highlight class I histone deacetylase (HDAC) inhibitors, including MS‐275 (Entinostat), as increasing ROS in sarcoma cells and blocking their capacity for invasion and metastasis in vivo. Here, HDAC9 is linked to sarcoma.